Safety of HRX215 in Patients After Minor and Major Liver Resection

Recruiting now · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Liver Resection, Colorectal Carcinoma Liver Metastases

In brief

The goal of this clinical trial is to learn if HRX215 is safe, tolerable and active in adults who have undergone liver resection due to colorectal carcinoma metastases. The objectives are: 1. to learn about the safety and tolerability of HRX215 2. to learn about how the body absorbs, distributes, and gets rid of HRX215. 3. to learn about clinical activity of HRX215 Researchers will compare HRX215 to a placebo (a look-alike substance that contains no drug) to investigate safety, tolerability and clinical activity in participants taking HRX215.

Key facts

Study ID
NCT06638502
Run by
HepaRegeniX GmbH
People needed
80
Starts
2025-05-06
Expected to finish
2027-12-31
Last updated by the study team
2026-07-30

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.